Cargando...
Progressive renal insufficiency related to ALK inhibitor, alectinib
Alectinib is a second generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor and is generally effective and tolerated in patients who have demonstrated disease progression or adverse effects while on the first generation inhibitor, crizotinib. ALK inhibitors can cause a reversible chr...
Gardado en:
| Publicado en: | Oxf Med Case Reports |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Oxford University Press
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5915949/ https://ncbi.nlm.nih.gov/pubmed/29713488 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/omcr/omy009 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|